CD8A and neoplasm: Due to the presence of, inter alia, high levels of PD-1+ CD8+ T cells in the tumour microenvironment, especially at relapse after bone marrow transplant, AML is a potential candidate for therapeutic modulation of that immune checkpoint molecule [8,9].